CureVac NV logo

5CV - CureVac NV Share Price

€34.75 -0.4  -1.1%

Last Trade - 10:33am

Large Cap
Market Cap £5.40bn
Enterprise Value £4.33bn
Revenue £41.2m
Position in Universe 170th / 1059
Unlock 5CV Revenue
Relative Strength (%)
1m -28.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -72.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 12.9 17.4 48.9 145.6 1,909 +94.9%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, CureVacBV revenues increased from EUR17.4M to EUR48.9M. Net lossincreased 29% to EUR129.1M. Revenues reflect United Statessegment increase from EUR14.3M to EUR34.9M, Switzerlandsegment increase of 34% to EUR695K. Higher net lossreflects Research and development expenses increase fromEUR28.4M to EUR79.6M (expense), Finance expenses increasefrom EUR636K to EUR20.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


5CV Revenue Unlock 5CV Revenue

Net Income

5CV Net Income Unlock 5CV Revenue

Normalised EPS

5CV Normalised EPS Unlock 5CV Revenue

PE Ratio Range

5CV PE Ratio Range Unlock 5CV Revenue

Dividend Yield Range

5CV Dividend Yield Range Unlock 5CV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
5CV EPS Forecasts Unlock 5CV Revenue
Profile Summary

CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
No. of Shareholders: n/a
No. of Employees: 500
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Frankfurt Stock Exchange (Dual Listing)
Shares in Issue 186,599,758
Free Float (0.0%)
Eligible for
5CV Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for 5CV
Upcoming Events for 5CV
Frequently Asked Questions for CureVac NV
What is the CureVac NV share price?

As of 10:33am, shares in CureVac NV are trading at €34.75, giving the company a market capitalisation of £5.40bn. This share price information is delayed by 15 minutes.

How has the CureVac NV share price performed this year?

Shares in CureVac NV are currently trading at €34.75 and the price has moved by -23.53% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CureVac NV price has moved by -39.71% over the past year.

What are the analyst and broker recommendations for CureVac NV?

There are no analysts currently covering CureVac NV.

When will CureVac NV next release its financial results?

CureVac NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the CureVac NV dividend yield?

CureVac NV does not currently pay a dividend.

Does CureVac NV pay a dividend?

CureVac NV does not currently pay a dividend.

When does CureVac NV next pay dividends?

CureVac NV does not currently pay a dividend.

How do I buy CureVac NV shares?

To buy shares in CureVac NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CureVac NV?

Shares in CureVac NV are currently trading at €34.75, giving the company a market capitalisation of £5.40bn.

Where are CureVac NV shares listed? Where are CureVac NV shares listed?

Here are the trading details for CureVac NV:

Country of listing: Germany
Exchange: FRA
Ticker Symbol: 5CV
What kind of share is CureVac NV?

Based on an overall assessment of its quality, value and momentum, CureVac NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CureVac NV share price forecast 2021?

Shares in CureVac NV are currently priced at €34.75. At that level they are trading at 74.37% discount to the analyst consensus target price of 0.00.

Analysts covering CureVac NV currently have a consensus Earnings Per Share (EPS) forecast of -2.4574371552 for the next financial year.

How can I tell whether the CureVac NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CureVac NV. Over the past six months, the relative strength of its shares against the market has been -63.94%. At the current price of €34.75, shares in CureVac NV are trading at -50.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CureVac NV PE Ratio?

We were not able to find PE ratio data for CureVac NV.

Who are the key directors of CureVac NV?

CureVac NV's management team is headed by:

Franz-Werner Haas - CEO
Florian Von der Mulbe - MGB
Mariola Fotin-Mleczek - CTO
Pierre Kemula - CFO
Antony Blac - MGB
Senta Gnad-Vogt - MGB
Igor Splawski - CSO
Baron Stephenne - CSU
Ralf Clemens - SUB
Mathias Hothum - SUB
Hans Tanner - IND
Friedrich von Bohlen und Halbach - VSU
Craig Tooman - IND
Viola Bronsema - SUB
Who are the major shareholders of CureVac NV?

Here are the top five shareholders of CureVac NV based on the size of their shareholding:

DH Capital GmbH & Co. KG Corporation
Percentage owned: 42.37% (79.1m shares)
KfW Bank and Trust
Percentage owned: 16.01% (29.9m shares)
Glaxo Group, Ltd. Holding Company
Percentage owned: 8% (14.9m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 2.96% (5.52m shares)
Bill & Melinda Gates Foundation Foundation
Percentage owned: 1.68% (3.13m shares)
Similar to 5CV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.